---
title: "Invivyd, Inc. (IVVD.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/IVVD.US.md"
symbol: "IVVD.US"
name: "Invivyd, Inc."
industry: "Biotechnology"
datetime: "2026-05-19T16:10:21.744Z"
locales:
  - [en](https://longbridge.com/en/quote/IVVD.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/IVVD.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/IVVD.US.md)
---

# Invivyd, Inc. (IVVD.US)

## Company Overview

Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in  pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.invivyd.com](https://www.invivyd.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:14.000Z

**Overall: B (0.38)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 45 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 52.27% |  |
| Net Profit YoY | 45.63% |  |
| P/B Ratio | 1.57 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 319568365.19 |  |
| Revenue | 55866000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -60.34% | E |
| Profit Margin | -138.90% | E |
| Gross Margin | 92.49% | A |
| Revenue YoY | 52.27% | A |
| Net Profit YoY | 45.63% | B |
| Total Assets YoY | 133.02% | A |
| Net Assets YoY | 274.98% | A |
| Cash Flow Margin | 101.44% | C |
| OCF YoY | 52.27% | A |
| Turnover | 0.32 | D |
| Gearing Ratio | 16.01% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Invivyd, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "52.27%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "45.63%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.57",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "319568365.19",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "55866000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "-60.34%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-138.90%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "92.49%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "52.27%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "45.63%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "133.02%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "274.98%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "101.44%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "52.27%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.32",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "16.01%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -4.12 | 353/386 | - | - | - |
| PB | 1.57 | 151/386 | 6.21 | 4.43 | 1.67 |
| PS (TTM) | 5.72 | 119/386 | 10.39 | 7.57 | 2.61 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-19T04:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.09 |
| Highest Target | 10.00 |
| Lowest Target | 10.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/IVVD.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/IVVD.US/norm.md)
- [Related News](https://longbridge.com/en/quote/IVVD.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/IVVD.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**